The GI-focused privately held Swiss company Ferring Pharmaceuticals has moved more extensively into the hot microbiome research area by announcing plans to set up a microbiome translation research program in a strategic collaboration with Sweden's Karolinska Institute, whose research teams have a long history of studying bacterial populations.
The collaboration follows Ferring's move into the related bacteriophage research area last year, and in which a clinical trial is expected to start by the end of the year,
